Sensus reported a FY 2025 net loss of USD 7.7 million, or USD (0.47) per diluted share, on revenue of USD 27.5 million (down 34%). Gross profit was USD 11.9 million, with gross margin of 43.3%. Operating loss was USD 10.3 million. Total operating expenses were USD 22.2 million, including general and administrative expense of USD 7.9 million, selling and marketing expense of USD 6.5 million, and research and development expense of USD 7.8 million. Interest income, net was USD 0.7 million. For FY 2025, net cash provided by operating activities was USD 0.5 million, and cash and cash equivalents were USD 22.1 million at December 31, 2025. Accounts receivable, net was USD 6.0 million at year-end, while inventories were USD 14.6 million. In business updates, Sensus said FY 2025 revenue was impacted by reduced sales to its historically largest customer and lower unit volumes (70 units in FY 2025). The company highlighted revenue recognized from new placements under its Fair Deal Agreement program, which also drove higher installation and training costs ahead of related revenues. Sensus also cited significant lobbying costs in FY 2025 tied to securing billing code reimbursement, and noted CMS revalued and increased SRT reimbursement effective January 1, 2026, which management expects to increase demand for its SRT product.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensus Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001753926-26-000435), on March 04, 2026, and is solely responsible for the information contained therein.
Comments